Dr. Benjamin Vincent on why the FDA approval of daraxonrasib is a major breakthrough for advanced pancreatic cancer: "Daraxonrasib is super exciting. A RAS inhibitor drug that works on one of the main molecular drivers associated with pancreatic cancer incidence and progression, and has had exceptional response rates even with advanced and metastatic disease." "It got a standing ovation at the ASCO meeting this year, which is a major meeting held early summer. I'm extremely gratified to see…